Literature DB >> 18623088

IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer.

Stuart G Reeves1, Dominique Rich, Cliff J Meldrum, Kim Colyvas, Grzegorz Kurzawski, Janina Suchy, Jan Lubinski, Rodney J Scott.   

Abstract

Patients diagnosed with HNPCC harbouring a confirmed germline mutation in DNA mismatch repair (MMR) genes have an 80% lifetime risk of developing an epithelial malignancy. There is, however, considerable variation in the age of disease onset in these patients. Insulin-like growth factor-I (IGFI) has been implicated in colorectal cancer (CRC), and elevated plasma IGFI levels are associated with both sporadic and hereditary CRC risk. In this study, we further investigate the cytosine-adenine (CA) dinucleotide repeat polymorphism located near the promoter region of IGF1 and its relation to early onset CRC risk in 443 Australian and Polish MMR gene mutation carriers using DNA sequencing, Kaplan-Meier survival curves and Cox proportional hazard regression analysis. A significantly smaller number of IGF1 CA repeats was observed in the Polish patient population, which was associated with an earlier age of disease onset compared to the Australian patients. The threshold for the observed modifying effect was again shown to be in patients with 17 or less CA repeats compared to those with 18 or more. Furthermore, when MMR mutation group (i.e., MLH1 or MSH2), gender and family clustering were included in the final Cox model we observed a more robust trend for the role of the IGF1 CA repeat in predicting age of disease onset in HNPCC patients. In addition, this effect was shown to be equal in both MLH1 and MSH2 mutation carrier groups and not restricted to a particular MMR subgroup (p = 0.001). We conclude that the IGF1 CA repeat is an important modifier of disease onset in HNPCC and the first polymorphism to yield consistent results across different populations. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18623088     DOI: 10.1002/ijc.23668

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

Review 1.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

2.  Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers.

Authors:  Solene Houlle; Françoise Charbonnier; Estelle Houivet; Julie Tinat; Marie-Pierre Buisine; Olivier Caron; Jacques Benichou; Stéphanie Baert-Desurmont; Thierry Frebourg
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

3.  Association of insulin-like growth factor-I receptor polymorphism with colorectal cancer development.

Authors:  Noyko S Stanilov; Iliya A Karakolev; Tashko S Deliysky; Jovcho P Jovchev; Spaska A Stanilova
Journal:  Mol Biol Rep       Date:  2014-09-05       Impact factor: 2.316

Review 4.  Hereditary and familial colon cancer.

Authors:  Kory W Jasperson; Thérèse M Tuohy; Deborah W Neklason; Randall W Burt
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

5.  Genes in the insulin and insulin-like growth factor pathway and odds of metachronous colorectal neoplasia.

Authors:  Elizabeth C LeRoy; Jason H Moore; Chengcheng Hu; María Elena Martínez; Peter Lance; David Duggan; Patricia A Thompson
Journal:  Hum Genet       Date:  2011-01-11       Impact factor: 4.132

6.  IGF gene polymorphisms and breast cancer in African-American and Hispanic women.

Authors:  Marianna Sarkissyan; Dhruva Kumar Mishra; Yanyuan Wu; Xiying Shang; Suren Sarkissyan; Jaydutt V Vadgama
Journal:  Int J Oncol       Date:  2011-03-30       Impact factor: 5.650

7.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.

Authors:  Aung Ko Win; Joanne P Young; Noralane M Lindor; Katherine M Tucker; Dennis J Ahnen; Graeme P Young; Daniel D Buchanan; Mark Clendenning; Graham G Giles; Ingrid Winship; Finlay A Macrae; Jack Goldblatt; Melissa C Southey; Julie Arnold; Stephen N Thibodeau; Shanaka R Gunawardena; Bharati Bapat; John A Baron; Graham Casey; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; John L Hopper; Mark A Jenkins
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

8.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

9.  Developmental and oncogenic effects of insulin-like growth factor-I in Ptc1+/- mouse cerebellum.

Authors:  Mirella Tanori; Melissa Santone; Mariateresa Mancuso; Emanuela Pasquali; Simona Leonardi; Vincenzo Di Majo; Simonetta Rebessi; Anna Saran; Simonetta Pazzaglia
Journal:  Mol Cancer       Date:  2010-03-09       Impact factor: 27.401

10.  Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome.

Authors:  Jinyun Chen; Carol J Etzel; Christopher I Amos; Qing Zhang; Nancy Viscofsky; Noralane M Lindor; Patrick M Lynch; Marsha L Frazier
Journal:  Cancer Causes Control       Date:  2009-08-19       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.